Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients

Journal of Immunology

Volumn 189, Issue 7, 2012, Pages 3751-3758

  Kim, Min Jeong ^a,b   McDaid, John P ^a   McAdoo, Stephen P ^a   Barratt, Jonathan ^c   Molyneux, Karen ^c   Masuda, Esteban S ^d   Pusey, Charles D ^a   Tam, Frederick W K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSTAMATINIB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN A1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE SYK; RANTES; SMALL INTERFERING RNA;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; MESANGIUM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; CYTOKINES; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; INFLAMMATION MEDIATORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MESANGIAL CELLS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SPLEEN;

EID: 84866560703     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102603     Document Type: Article

References (40)

1. Conley, M. E., M. D. Cooper, and A. F. Michael. 1980. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J. Clin. Invest. 66: 1432-1436. (Pubitemid 11205607)
2. Kerr, M. A. 1990. The structure and function of human IgA. Biochem. J. 271: 285-296. (Pubitemid 20344737)
3. Tomana, M., J. Novak, B. A. Julian, K. Matousovic, K. Konecny, and J. Mestecky. 1999. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J. Clin. Invest. 104: 73-81. (Pubitemid 29534347)
4. Allen, A. C., E. M. Bailey, P. E. C. Brenchley, K. S. Buck, J. Barratt, and J. Feehally. 2001. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int. 60: 969-973. (Pubitemid 34205796)
5. Novak, J., H. L. Vu, L. Novak, B. A. Julian, J. Mestecky, and M. Tomana. 2002. Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int. 62: 465-475. (Pubitemid 34779757)
6. Suzuki, H., R. Fan, Z. Zhang, R. Brown, S. Hall, B. A. Julian, W. W. Chatham, Y. Suzuki, R. J. Wyatt, Z. Moldoveanu, et al. 2009. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119: 1668-1677.
7. + mobilization in rat and human mesangial cells. J. Immunol. 156: 4369-4376.
8. Duque, N., C. Gómez-Guerrero, and J. Egido. 1997. Interaction of IgA with Fcα receptors of human mesangial cells activates transcription factor nuclear factor-κ B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J. Immunol. 159: 3474-3482. (Pubitemid 127482106)
9. Leung, J. C. K., S. C. W. Tang, L. Y. Y. Chan, A. W. L. Tsang, H. Y. Lan, and K. N. Lai. 2003. Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol. Dial. Transplant. 18: 36-45. (Pubitemid 36104476)
10. Lai, K. N., S. C. W. Tang, J. Y. Guh, T. D. Chuang, M. F. Lam, L. Y. Y. Chan, A. W. L. Tsang, and J. C. K. Leung. 2003. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-β synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J. Am. Soc. Nephrol. 14: 3127-3137. (Pubitemid 37509290)
11. Leung, J. C. K., S. C. W. Tang, L. Y. Y. Chan, W. L. Chan, and K. N. Lai. 2008. Synthesis of TNF-α by mesangial cells cultured with polymeric anionic IgA - role of MAPK and NF-κB. Nephrol. Dial. Transplant. 23: 72-81. (Pubitemid 351767388)
12. Tam, K. Y., J. C. K. Leung, L. Y. Y. Chan, M. F. Lam, S. C. W. Tang, and K. N. Lai. 2009. Macromolecular IgA1 taken from patients with familial IgA nephropathy or their asymptomatic relatives have higher reactivity to mesangial cells in vitro. Kidney Int. 75: 1330-1339.
13. Amore, A., P. Cirina, G. Conti, P. Brusa, L. Peruzzi, and R. Coppo. 2001. Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J. Am. Soc. Nephrol. 12: 1862-1871. (Pubitemid 32801361)
14. Novak, J., M. Tomana, K. Matousovic, R. Brown, S. Hall, L. Novak, B. A. Julian, R. J. Wyatt, and J. Mestecky. 2005. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 67: 504-513. (Pubitemid 40139842)
15. Moura, I. C., M. Benhamou, P. Launay, F. Vrtovsnik, U. Blank, and R. C. Monteiro. 2008. The glomerular response to IgA deposition in IgA nephropathy. Semin. Nephrol. 28: 88-95.
16. Taniguchi, T., T. Kobayashi, J. Kondo, K. Takahashi, H. Nakamura, J. Suzuki, K. Nagai, T. Yamada, S. Nakamura, and H. Yamamura. 1991. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J. Biol. Chem. 266: 15790-15796. (Pubitemid 21907727)
17. Wong, B. R., E. B. Grossbard, D. G. Payan, and E. S. Masuda. 2004. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin. Investig. Drugs 13: 743-762. (Pubitemid 39028928)
18. Cha, H. S., D. L. Boyle, T. Inoue, R. Schoot, P. P. Tak, P. Pine, and G. S. Firestein. 2006. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J. Pharmacol. Exp. Ther. 317: 571-578.
19. Mócsai, A., J. Ruland, and V. L. J. Tybulewicz. 2010. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10: 387-402.
20. Tsuge, T., Y. Suzuki, T. Shimokawa, S. Horikoshi, K. Okumura, C. Ra, and Y. Tomino. 2003. Monocyte chemoattractant protein (MCP)-1 production via functionally reconstituted Fcα receptor (CD89) on glomerular mesangial cells. Inflamm. Res. 52: 428-432. (Pubitemid 37260430)
21. Tam, F. W. K., and S. P. McAdoo. 2011. Fostamatinib disodium: tyrosine-protein kinase SYK/FLT3 inhibitor, treatment of rheumatoid arthritis, oncolytic. Drugs Future 36: 273-280.
22. Podolanczuk, A., A. H. Lazarus, A. R. Crow, E. Grossbard, and J. B. Bussel. 2009. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113: 3154-3160.
23. Friedberg, J. W., J. Sharman, J. Sweetenham, P. B. Johnston, J. M. Vose, A. Lacasce, J. Schaefer-Cutillo, S. De Vos, R. Sinha, J. P. Leonard, et al. 2010. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585.
24. Weinblatt, M. E., A. Kavanaugh, M. C. Genovese, T. K. Musser, E. B. Grossbard, and D. B. Magilavy. 2010. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363: 1303-1312.
25. Smith, J., J. P. McDaid, G. Bhangal, R. Chawanasuntorapoj, E. S. Masuda, H. T. Cook, C. D. Pusey, and F. W. K. Tam. 2010. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J. Am. Soc. Nephrol. 21: 231-236.
26. Braselmann, S., V. Taylor, H. Zhao, S. Wang, C. Sylvain, M. Baluom, K. Qu, E. Herlaar, A. Lau, C. Young, et al. 2006. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319: 998-1008.
27. Gómez-Guerrero, C., M. J. López-Armada, E. González, and J. Egido. 1994. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-α and IL-6, and proliferation. J. Immunol. 153: 5247-5255. (Pubitemid 24983927)
28. Boyd, J. K., C. K. Cheung, K. Molyneux, J. Feehally, and J. Barratt. 2012. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 81: 833-843.
29. Chan, L. Y. Y., J. C. K. Leung, A. W. L. Tsang, S. C. W. Tang, and K. N. Lai. 2005. Activation of tubular epithelial cells by mesangial-derived TNF-α: glomerulotubular communication in IgA nephropathy. Kidney Int. 67: 602-612. (Pubitemid 40139851)
30. Lai, K. N., J. C. K. Leung, L. Y. Y. Chan, M. A. Saleem, P. W. Mathieson, K. Y. Tam, J. Xiao, F. M. Lai, and S. C. W. Tang. 2009. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol. Dial. Transplant. 24: 62-72.
31. Coppo, R., V. Fonsato, S. Balegno, E. Ricotti, E. Loiacono, R. Camilla, L. Peruzzi, A. Amore, B. Bussolati, and G. Camussi. 2010. Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int. 77: 417-427.
32. Grandaliano, G., L. Gesualdo, E. Ranieri, R. Monno, V. Montinaro, F. Marra, and F. P. Schena. 1996. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J. Am. Soc. Nephrol. 7: 906-913. (Pubitemid 27465985)
33. Yokoyama, H., T. Wada, K. Furuichi, C. Segawa, M. Shimizu, K. Kobayashi, S. Su, N. Mukaida, and K. Matsushima. 1998. Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J. Leukoc. Biol. 63: 493-499. (Pubitemid 28163190)
34. Stangou, M., E. Alexopoulos, A. Papagianni, A. Pantzaki, C. Bantis, S. Dovas, D. Economidou, M. Leontsini, and D. Memmos. 2009. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology 14: 613-620.
35. Lim, C. S., H. J. Yoon, Y. S. Kim, C. Ahn, J. S. Han, S. Kim, J. S. Lee, H. S. Lee, and D. W. Chae. 2003. Clinicopathological correlation of intrarenal cytokines and chemokines in IgA nephropathy. Nephrology 8: 21-27. (Pubitemid 36237947)
36. Boor, P., F. Eitner, C. D. Cohen, M. T. Lindenmeyer, P. R. Mertens, T. Ostendorf, and J. Floege. 2009. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrol. Dial. Transplant. 24: 2755-2762.
37. Segerer, S., P. J. Nelson, and D. Schlöndorff. 2000. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J. Am. Soc. Nephrol. 11: 152-176. (Pubitemid 30020438)
38. Berthelot, L., Ch. Papista, T. T. Maciel, M. Biarnes-Pelicot, E. Tissandie, P. H. M. Wang, H. Tamouza, A. Jamin, J. Bex-Coudrat, A. Gestin, et al. 2012. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J. Exp. Med. 209: 793-806.
39. Weinblatt, M. E., A. Kavanaugh, R. Burgos-Vargas, A. H. Dikranian, G. Medrano-Ramirez, J. L. Morales-Torres, F. T. Murphy, T. K. Musser, N. Straniero, A. V. Vicente-Gonzales, and E. Grossbard. 2008. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58: 3309-3318.
40. Scott, D. L. 2011. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs 71: 1121-1132.